(Date:11/6/2009)...NBROOK, N.Y., Nov. 6 Bio...iopharmaceutical company developing first-in-class...inancial results for the third quarter ended Septe...t, in September of this year, the FDA,s Arthritis ...ote of 12-0, the approval of XIAFLEX(TM) for the t...
(Date:11/6/2009)...RING VALLEY, Calif., Nov. 6 Calbio...d a Small Business Innovative Research (SBIR) Phas... Material command. Under terms of the agreement, C...ASRs) for the diagnosis of Dengue virus. ,, ...presents a major threat to military forces deploye...
(Date:11/5/2009)...ITHERSBURG, Md., Nov. 5 ...financial results for the third quarter ended Sept... million ($0.04 per share) for the three months en...6.8 million ($0.08 per share) in the comparable qu... 30, 2009, GenVec,s net loss was $14.1 million ($0...
(Date:11/5/2009)...nference Call on Thursday, November 5, 2009 at 4:3...ER Nov. 5 /PRNewswire-FirstCall/ - OncoGenex Pharm...ASDAQ: OGXI ) today reported unaudited financial ...d September 30, 2009 and reviewed the Company,s hi...following consolidated results reflect the operati...
Breaking Biology Technology:Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 6Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus 2GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8... May 12 WaferGen Biosystems,Inc. (OTC Bulletin Bo...t,gene expression, genotyping, cell biology and st...Alnoor Shivji, President and Chief Executive,Offic...odman & Renshaw,Fifth Annual Global Healthcare Con...08, at the Le Meridien Beach Plaza Hotel in Monte ...
...f., May 9 Bionovo, Inc.,(Nasdaq: BNVI ) today an...uarter Results, The company did not report any re...evenues for the three months ended March 31, 2007 ...logy transfer agreement with United,Biotechnology ...inated the,agreement following notice of material ...
... May 9 Alexion,Pharmaceuticals, Inc. (Nasdaq: AL...esentation at the Bank of America 2008 Health Care...p.m., local time (7:00 p.m., eastern),on Tuesday, ...nd Chief,Financial Officer, is scheduled to presen...be available live. You can,access the webcast at: ...
Other Biology Technology:WaferGen to Present at the Rodman and Renshaw Fifth Annual Global Healthcare Conference 2Bionovo Reports First Quarter 2008 Financial Results 2Bionovo Reports First Quarter 2008 Financial Results 3Bionovo Reports First Quarter 2008 Financial Results 4Bionovo Reports First Quarter 2008 Financial Results 5Bionovo Reports First Quarter 2008 Financial Results 6...300 (YELLOW), 1 EA. Ultrospec 6300 pro UV/Visibl...ements of the Pharmacopoeia in terms of instrument...benefits of being able to be used for rapid, discr...ent scanning capability., *Press to read high perf...
Cy3 Ab Labeling Kit from GE Healthcare, formerly Amersham Biosciences
Rabbit Anti-NPM1 Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
QuantiChrom Zinc Assay Kit from BioAssay Systems
Biology Products: